133 related articles for article (PubMed ID: 12770925)
1. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.
Herold CL; Behm DJ; Buckley PT; Foley JJ; Wixted WE; Sarau HM; Douglas SA
Br J Pharmacol; 2003 May; 139(2):203-7. PubMed ID: 12770925
[TBL] [Abstract][Full Text] [Related]
2. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.
Behm DJ; Herold CL; Ohlstein EH; Knight SD; Dhanak D; Douglas SA
Br J Pharmacol; 2002 Oct; 137(4):449-58. PubMed ID: 12359626
[TBL] [Abstract][Full Text] [Related]
4. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
Camarda V; Song W; Marzola E; Spagnol M; Guerrini R; Salvadori S; Regoli D; Thompson JP; Rowbotham DJ; Behm DJ; Douglas SA; Calo' G; Lambert DG
Eur J Pharmacol; 2004 Sep; 498(1-3):83-6. PubMed ID: 15363979
[TBL] [Abstract][Full Text] [Related]
5. A new ligand for the urotensin II receptor.
Camarda V; Guerrini R; Kostenis E; Rizzi A; Calò G; Hattenberger A; Zucchini M; Salvadori S; Regoli D
Br J Pharmacol; 2002 Oct; 137(3):311-4. PubMed ID: 12237249
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle.
Behm DJ; Ao Z; Camarda V; Aiyar NV; Johns DG; Douglas SA
Eur J Pharmacol; 2005 Jun; 516(3):276-81. PubMed ID: 15975570
[TBL] [Abstract][Full Text] [Related]
7. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.
Patacchini R; Santicioli P; Giuliani S; Grieco P; Novellino E; Rovero P; Maggi CA
Br J Pharmacol; 2003 Dec; 140(7):1155-8. PubMed ID: 14645137
[TBL] [Abstract][Full Text] [Related]
8. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.
Douglas SA; Behm DJ; Aiyar NV; Naselsky D; Disa J; Brooks DP; Ohlstein EH; Gleason JG; Sarau HM; Foley JJ; Buckley PT; Schmidt DB; Wixted WE; Widdowson K; Riley G; Jin J; Gallagher TF; Schmidt SJ; Ridgers L; Christmann LT; Keenan RM; Knight SD; Dhanak D
Br J Pharmacol; 2005 Jul; 145(5):620-35. PubMed ID: 15852036
[TBL] [Abstract][Full Text] [Related]
9. Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.
Song W; McDonald J; Camarda V; Calo G; Guerrini R; Marzola E; Thompson JP; Rowbotham DJ; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2006 May; 373(2):148-57. PubMed ID: 16596397
[TBL] [Abstract][Full Text] [Related]
10. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.
Behm DJ; Herold CL; Camarda V; Aiyar NV; Douglas SA
Eur J Pharmacol; 2004 May; 492(2-3):113-6. PubMed ID: 15178353
[TBL] [Abstract][Full Text] [Related]
11. Urotensin-II receptor ligands. From agonist to antagonist activity.
Grieco P; Carotenuto A; Campiglia P; Marinelli L; Lama T; Patacchini R; Santicioli P; Maggi CA; Rovero P; Novellino E
J Med Chem; 2005 Nov; 48(23):7290-7. PubMed ID: 16279788
[TBL] [Abstract][Full Text] [Related]
12. Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.
Douglas SA; Naselsky D; Ao Z; Disa J; Herold CL; Lynch F; Aiyar NV
Br J Pharmacol; 2004 Jul; 142(6):921-32. PubMed ID: 15210573
[TBL] [Abstract][Full Text] [Related]
13. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.
Rossowski WJ; Cheng BL; Taylor JE; Datta R; Coy DH
Eur J Pharmacol; 2002 Mar; 438(3):159-70. PubMed ID: 11909607
[TBL] [Abstract][Full Text] [Related]
14. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
Behm DJ; Harrison SM; Ao Z; Maniscalco K; Pickering SJ; Grau EV; Woods TN; Coatney RW; Doe CP; Willette RN; Johns DG; Douglas SA
Br J Pharmacol; 2003 May; 139(2):464-72. PubMed ID: 12770952
[TBL] [Abstract][Full Text] [Related]
15. Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay.
Brkovic A; Hattenberger A; Kostenis E; Klabunde T; Flohr S; Kurz M; Bourgault S; Fournier A
J Pharmacol Exp Ther; 2003 Sep; 306(3):1200-9. PubMed ID: 12807997
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor.
Batuwangala M; Camarda V; McDonald J; Marzola E; Lambert DG; Ng LL; Calo' G; Regoli D; Trapella C; Guerrini R; Salvadori S
Peptides; 2009 Jun; 30(6):1130-6. PubMed ID: 19463746
[TBL] [Abstract][Full Text] [Related]
17. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction.
Giebing G; Tölle M; Jürgensen J; Eichhorst J; Furkert J; Beyermann M; Neuschäfer-Rube F; Rosenthal W; Zidek W; van der Giet M; Oksche A
Circ Res; 2005 Sep; 97(7):707-15. PubMed ID: 16141412
[TBL] [Abstract][Full Text] [Related]
18. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
Camarda V; Rizzi A; Calò G; Gendron G; Perron SI; Kostenis E; Zamboni P; Mascoli F; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):141-9. PubMed ID: 11819032
[TBL] [Abstract][Full Text] [Related]
19. Urotensin II evokes neurotransmitter release from rat cerebrocortical slices.
Ono T; Kawaguchi Y; Kudo M; Kushikata T; Hashiba E; Yoshida H; Kudo T; Furukawa K; Douglas SA; Guerrini R; Calo' G; Hirota K
Neurosci Lett; 2008 Aug; 440(3):275-9. PubMed ID: 18572318
[TBL] [Abstract][Full Text] [Related]
20. GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.
Behm DJ; Aiyar NV; Olzinski AR; McAtee JJ; Hilfiker MA; Dodson JW; Dowdell SE; Wang GZ; Goodman KB; Sehon CA; Harpel MR; Willette RN; Neeb MJ; Leach CA; Douglas SA
Br J Pharmacol; 2010 Sep; 161(1):207-28. PubMed ID: 20718751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
